Presentation on the biosimilar Enoxaparin of ROVI


No votes yet
 
Related
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
​Operating revenue in the first quarter of 2025 was 154.9 million euros, a 2% increase on the first quarter of 2024, mainly due to the...
2 min
08/05/2025